Key result
Ex vivo treatment with ARC1779 at 83 and 250 nmol/L reduced platelet adhesion compared to placebo (4.8 and × 10(6)/cm2;).
Why the study?
Does the anti-vWF aptamer ARC1779 reduce ex vivo platelet adhesion in blood from CAD patients on dual antiplatelet therapy?
Does the anti-vWF aptamer ARC1779 reduce ex vivo platelet adhesion in blood from CAD patients on dual antiplatelet therapy?
The anti-vWF aptamer ARC1779 reduces ex vivo platelet adhesion without affecting aggregation in blood from CAD patients on dual antiplatelet therapy, suggesting a potential site-specific antithrombotic effect.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for vWF aptamer adjunctive effects in CAD; leaves open in vivo efficacy and safety on DAPT.
The von Willebrand factor (vWF) aptamer, ARC1779 that blocks the binding of vWF A1-domain to platelet glycoprotein 1b (GPIb) at high shear, may deliver a site-specific antithrombotic effect. We investigated the efficiency of ARC1779 on platelet function in patients with coronary artery disease (CAD) on double antiplatelet therapy. Blood from patients taking aspirin and clopidogrel and from normal volunteers was treated ex vivo with ARC1779 or abciximab, either prior to perfusion (pretherapy) or 10 minutes following the initiation of perfusion (posttherapy) on damaged arteries. Under pre- but not posttherapy, platelet adhesion was significantly reduced by ARC1779 at 83 and 250 nmol/L and by abciximab (100 nmol/L) versus placebo (4.8, 3.8, and 2.9 vs 7.3 platelets × 10(6)/cm(2), P < .05). In contrast to abciximab, ARC1779 did not significantly affect platelet aggregation, P-selectin expression, and platelet-leukocyte binding. These proof-of-concept data may constitute the framework for randomized clinical investigations of this novel antiplatelet therapy among patients with CAD.
No takes yet. Share an insight, caveat, or question.
Arzamendi et al. (2010) studied Coronary artery disease (CAD). ARC1779 vs. Placebo and abciximab was evaluated on Platelet adhesion (p=< .05). Ex vivo treatment with ARC1779 at 83 and 250 nmol/L reduced platelet adhesion compared to placebo (4.8 and × 10(6)/cm2;).
Synapse has enriched 10 related papers. Consider them for comparative context: